In patients with liver disease at risk of pulmonary oedema, cryoprecipitate (small volume) might be a viable alternative to fresh frozen plasma (FFP, large volume) in the correction of coagulopathy. However, the efficacy of cryoprecipitate in these patients has not been tested. We evaluated the role of cryoprecipitate in the correction of the coagulopathy of liver disease. To establish initial evidence of efficacy, six consecutive patients with hepatic failure and coagulopathy received five units of cryoprecipitate. Then, using a crossover design, 11 consecutive patients were randomized to receive either four units of FFP or five units of cryoprecipitate. Pre and post infusion International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen D-dimers, Factors V and IX, and reptilase time were measured. In the first six patients, cryoprecipitate improved the INR, aPTT and fibrinogen concentration (P=0.03). In the crossover study, FFP administration produced a greater improvement in INR (P=0.007) and aPTT (P=0.005) than cryoprecipitate. However, there were no differences in any of the other measured variables. One patient developed acute pulmonary oedema while receiving FFP. Cryoprecipitate improves the coagulopathy of liver disease. Four units of FFP are more efficacious than five units of cryoprecipitate. Cryoprecipitate may have a role in correction of the coagulopathy associated with liver disease where concerns about pulmonary oedema exist.
Anaesthetists and intensivists may deal with patients with hepatic failure in whom the rapid correction of coagulopathy is necessary to facilitate the safe performance of invasive procedures or to treat bleeding. The best method to achieve such rapid correction of liver coagulopathy is unknown. Despite the lack of controlled studies, fresh frozen plasma (FFP) is typically given [1] [2] [3] [4] . The rationale for this treatment is that FFP is rich in the clotting factors believed to be deficient in liver disease. FFP, however, is presented in a volume of 180-240 ml and large amounts (>4 units) are often administered. The rapid administration of such volumes of fluid may induce acute pulmonary oedema.
On the other hand, cryoprecipitate, also a single donor preparation, is presented in a volume of 30 ml and is rich in fibrinogen, Factor VIII, von Willebrand Factor, Factor IX, Factor XI, Factor XII, Factor XIII and fibronectin 5 . However, the efficacy of cryoprecipitate in coagulopathy associated with liver disease has never been studied.
We hypothesized that cryoprecipitate may be a useful alternative to FFP, particularly when rapid correction of liver coagulopathy is needed, for example prior to line insertion or surgery. Accordingly, we performed two sequential studies: 1. a prospective observational study to determine the efficacy of cryoprecipitate on the coagulopathy of liver disease and 2. a prospective randomized crossover study to compare cryoprecipitate to fresh frozen plasma for the correction of the coagulopathy of liver disease.
MATERIALS AND METHODS
Local institutional Ethics Committee approval was obtained for these studies. Informed consent was obtained from the patient or next of kin.
Patient selection
Patients with documented hepatic failure (fulminant, subfulminant, and chronic) admitted to the intensive care unit who had a coagulopathy attributable to liver disease were eligible for enrolment. For the purposes of this study, coagulopathy was defined as an Activated Partial Thromboplastin Time (aPTT) or International Normalized Ratio (INR) greater than twice normal. Patients were excluded if they had received a previous hepatic transplant, were actively bleeding, or their coagulopathy was not attributable to liver disease.
Dose
Using retrospective chart analysis, we identified the most common doses of FFP and cryoprecipitate administered to ICU patients in our institution (standard practice). We found this to be approximately four units and five units respectively.
Study design
We conducted two separate studies. In the observational study, six patients were recruited. Patients received five units of cryoprecipitate over less than one hour. Blood samples were drawn immediately prior to administration for the measurement of INR, aPTT, fibrinogen, D-dimer, Factor VIII, von Willebrand Factor Antigen (vWFAg), and von Willebrand Factor (vWF) levels and TEG (thromboelastography, Haemoscope, Skokie, IL). Ten minutes after the administration of cryoprecipitate the above tests were repeated.
In the second study, eleven patients were randomized to receive either four units of FFP (720-960 ml) or five units of cryoprecipitate (150 ml). Twenty-four hours after treatment the patients crossed over to the alternative therapy if coagulopathy was still present. The following measurements were performed: INR, aPTT, fibrinogen, D-dimer, Factor VIII, Factor V, Factor IX, and reptilase time. Factor V and IX measurements were included in the second study because of their high concentrations in FFP.
Statistics
Statistical analysis was performed using Statview (Abacus Concepts Inc. Berkeley, CA.). Wilcoxon's signed rank test was used for comparisons between paired measurements (pre vs post treatment or crossover comparison of effect of two treatments in the same patient). The Mann-Whitney U test was used for non-paired comparisons (comparison of effect of cryoprecipitate versus FFP inclusive of crossover and non-crossover patients). Median values and range are presented. A P value of <0.05 was considered statistically significant.
RESULTS
In the observational study the median age was 51 years (range 35-69). There were two females and four males. Two patients had idiopathic fulminant hepatic failure and four had decompensated chronic hepatic failure (one idiopathic and three due to hepatitis B). Table 1 displays the effect of cryoprecipitate on coagulation. Cryoprecipitate significantly improved INR, aPTT and plasma fibrinogen concentration.
A significant increase in the maximum amplitude of the TEG, a reflection of the absolute strength of the fibrin clot 6 , was observed in all patients (13 mm vs 23 mm, P=0.04). Figure 1 displays a representative TEG (patient number 4) before and after the administration of cryoprecipitate.
The median age of the eleven patients enrolled in the crossover study was 55. There were six females and five males. One had fulminant hepatic failure, the remaining ten had decompensated chronic liver disease (4 hepatitis B, 2 alcoholic liver disease, 1 primary biliary cirrhosis, 1 metastatic small cell lung cancer, and 3 idiopathic).
Six of the 11 patients successfully crossed over. In four cases coagulopathy did not recur; therefore these patients only received the first arm of treatment (2 FFP only, and 2 cryoprecipitate only). One patient randomized to FFP was withdrawn due to the development of acute pulmonary oedema.
Four units of FFP produced a greater improvement in INR and aPTT than five units of cryoprecipitate. 
DISCUSSION
Cryoprecipitate is a single donor preparation formed when fresh frozen plasma is thawed at 4°C. Its contents and those of FFP are presented in Table 3 . It is rich in fibrinogen, Factor VIII, vWF and Factor XIII 5, 7 . Traditionally cryoprecipitate has been used therapeutically in haemophilia A and von Willebrand's disease, and congenital and acquired afibrinogenaemia and hypofibrinogenaemias 8 . Its use has also been described in uraemic bleeding, and for massive blood loss 7, 8 . Fresh frozen plasma is a single donor preparation whereby plasma is separated from whole blood within six to eight hours of donation and rapidly frozen to -30°C. It contains all coagulation factors plus complement. It has a volume of 180-240 ml 5 . Its use is advocated in the control and prevention of bleeding in patients with multiple coagulation defects (such as liver disease), patients taking coumarin anticoagulants requiring emergency surgery, and coumarin overdose. Its use has also been described in antithrombin III deficiency, thrombotic thrombocytopenic purpura and pseudocholinesterase deficiency [1] [2] [3] [4] 7 .
The aetiology of the coagulopathy of liver disease is multifactorial. The liver is the site of synthesis for coagulation factors (both pro-coagulant and anticoagulant) and it is also responsible for clearance of activated clotting factors. In addition, patients with cirrhosis have hypersplenism with associated thrombocytopenia and platelet dysfunction. Disseminated intravascular coagulation (DIC) has also been reported in association with hepatic failure possibly due to decreased clearance of t-PA and decreased synthesis of α 2 -antiplasmin 4, 7, [9] [10] [11] . The clinical picture of coagulopathy can vary widely, depending on the severity of the relative reduction in various factors, the presence of thrombocytopenia and platelet dysfunction and whether or not there is fibrinolysis. In our study all patients had a complex coagulopathy with major reductions in Factors V, IX and fibrinogen level and abnormal reptilase times, INR and aPTT. Factor VIII levels were not reduced. Significant variability in response to FFP has been observed [12] [13] [14] .
In our study we administered 960 ml (approximately 15 ml/kg) and a similar degree of variability was demonstrated (median improvement in INR of 34% range; 10%-45%).
We sought to determine whether a standard dose of cryoprecipitate (five units) was of comparable efficacy in the correction of the coagulopathy associated with liver disease to the standard dose of FFP (four units). The major differences between the two preparations are different concentrations of Factors II, V, VII, and IX. Our findings demonstrate that four units of FFP improved INR and aPTT to a greater degree than five units of cryoprecipitate. These amounts are not equivalent in terms of either volume or dose of coagulation factors. It is possible that increasing the amount of cryoprecipitate would achieve results similar to FFP, with still a substantial reduction in volume. Cryoprecipitate however is expensive; production costs per unit are approximately double that of FFP (Dr N. Boyce, personal communication).
The differences between the efficacy of cryoprecipitate and FFP effects on coagulation are possibly explained by the relative absence of Factors II, V and VII in cryoprecipitate. The number of patients studied is small but there appears to be no relationship between baseline coagulation parameters and degree of response. The effect of cryoprecipitate on coagulation measurements is difficult to fully explain. It does not appear to be due to the administration of Factor VIII or vWFAg since the levels of these factors were not reduced at baseline. The major effect, therefore, may be related to the improvement in fibrinogen. The amount of fibrinogen administered was 2.7 g with cryoprecipitate and 2.1 g with FFP. A trend to a greater increase in fibrinogen level with cryoprecipitate compared to FFP was observed (20% vs 7%, P=0.27).
In an effort to reduce the risk of volume overload other investigators have used prothrombin complex concentrates either alone or in combination with FFP 12, 15, 16 . They however contain activated Factors II, VII, IX and X. There is concern that these activated factors could produce thrombosis or DIC 15, 17 . The use of prothrombin complex concentrates in hepatic disease is not recommended 5 . The absence of any increase in D-dimer levels, together with the improvement in INR, does not support the occurrence of DIC or fibrinolysis with either FFP or cryoprecipitate. In the pilot study of cryoprecipitate, no patient's thromboelastogragh showed any evidence of fibrinolysis.
We demonstrated that cryoprecipitate, whilst not as efficacious as FFP, safely and reliably improves the coagulation profile of patients with hepatic failure. 
